ArticlePloS one2021
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.Multiple sclerosis and related disorders · 2022Pooled it
- Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.Frontiers in immunology · 2021Trial
- Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.Microorganisms · 2024Review
- Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort.Vaccines · 2024Article
- Era of COVID-19 in Multiple Sclerosis Care.Neurologic clinics · 2024Review
- INCREASED SEVERE COVID-19-RELATED FATALITY IN HOSPITALIZED MULTIPLE SCLEROSIS PATIENTS.Acta clinica Croatica · 2023Article
- Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Multiple Sclerosis Management During the COVID-19 Pandemic.Current neurology and neuroscience reports · 2022Review
- Impact of vaccination on COVID-19 outcome in multiple sclerosis.European journal of neurology · 2022Article
- Has the pandemic changed treatment strategy in multiple sclerosis?Multiple sclerosis and related disorders · 2022Article
- Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.European journal of neurology · 2022Article
- Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.Neurology and therapy · 2022Review
- Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?Clinical and experimental immunology · 2022Article
- Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.Journal of neurology · 2022Article
- Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.Journal of neurology · 2022Article
- Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis.iScience · 2021Article
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic challenges neurologists in counselling patients with multiple sclerosis (pwMS) regarding their risk by SARS-CoV-2 and in guiding disease-modifying treatment (DMT).
objectiveTo characterize the prevalence and outcome of COVID-19 in pwMS specifically associated with different DMT in a nationwide population-based study.
methodsWe included patients aged ≥18 years with a confirmed diagnosis of MS and a diagnosis of COVID-19 established between January 1, 2020 and December 31, 2020. We classified COVID-19 course as either mild, severe or fatal. Impact of DMT and specifically immunosuppressants (alemtuzumab, cladribine, fingolimod, ocrelizumab or rituximab) on COVID-19 outcome was determined by multivariable models, adjusted for a-priori-risk.
resultsOf 126 MS patients with COVID-19 (mean age 43.2 years [SD 13.4], 71% female), 86.5% had a mild course, 9.5% a severe course and 3.2% died from COVID-19. A-priori-risk significantly predicted COVID-19 severity (R2 0.814; p<0.001) and mortality (R2 0.664; p<0.001). Adjusting for this a-priori-risk, neither exposure to any DMT nor exposure to specific immunosuppressive DMT were significantly associated with COVID-19 severity (odds ratio [OR] 1.6; p = 0.667 and OR 1.9; p = 0.426) or mortality (OR 0.5; p = 0.711 and 2.1; 0.233) when compared to no DMT.
conclusionsIn a population-based MS cohort, COVID-19 outcome was not associated with exposure to DMT and immunosuppressive DMT when accounting for other already known risk factors. This provides reassuring evidence that COVID-19 risk can be individually anticipated in MS and-except for a very small proportion of high-risk patients-treatment decisions should be primarily focused on treating MS rather than the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.